The publication of this infographic was funded by AstraZeneca and is intended for US Healthcare Professionals only.
Treat-to-target care in systemic lupus erythematosus (SLE) focuses on defined goals like Definitions Of Remission In SLE (DORIS) remission or low disease activity, while minimizing glucocorticoid exposure.1,2 This infographic provides a concise visual summary of a Phase 3 study,3 including Week 52 endpoints and a safety snapshot.
Topics covered:
- Which treat-to-target goals matter most in lupus care?
- How is ‘remission’ defined in lupus (DORIS criteria)?
- What did data show at Week 52 versus placebo for the primary endpoint (BICLA response)?
- What do Week 52 data show for low disease activity, steroids, and safety?
References
1. American College of Rheumatology. Available at: https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/bltec93920aad624e33/sle-guideline-summary-2025.pdf. Last accessed: February 3, 2026
2. Fanouriakis A et al. Ann Rheum Dis. 2024;83(1):15-29.
3. Manzi S et al. Arthritis Rheumatol. 2025;DOI:10.1002/art.70041.
